IFF: Designing and validating clinically relevant probiotic strain combinations
16 Dec 2025 | IFF
IFF’s probiotics portfolio emphasizes clinically studied strain combinations. Johanna Maukonen, global director for clinical innovation and translation, and Jennifer Montgomery, IFF Health Sciences global marketing leader, discussed how IFF approaches designing and validating these formulas to ensure consistent benefits in real-world use, while sharing insights on key advances in the expanding field of probiotics for oral health.
















